Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks.
Research and practice in thrombosis and haemostasis
View this publicationResearch and practice in thrombosis and haemostasis
View this publicationBrain : a journal of neurology
View this publicationNEJM evidence
View this publicationMethods in enzymology
View this publicationInternational journal of obesity (2005)
View this publicationPloS one
View this publicationBlood
View this publicationEuropean journal of internal medicine
View this publicationHuman genetics
View this publicationAutoimmunity reviews
View this publication